Sick of Tourists, Japan Town Blocks View of Mt Fuji

Workers install a barrier to block the sight of Japan's Mount Fuji emerging from behind a convenience store to deter badly behaved tourists, in the town of Fujikawaguchiko, Yamanashi prefecture on May 21, 2024. (Photo by Kazuhiro NOGI / AFP)
Workers install a barrier to block the sight of Japan's Mount Fuji emerging from behind a convenience store to deter badly behaved tourists, in the town of Fujikawaguchiko, Yamanashi prefecture on May 21, 2024. (Photo by Kazuhiro NOGI / AFP)
TT

Sick of Tourists, Japan Town Blocks View of Mt Fuji

Workers install a barrier to block the sight of Japan's Mount Fuji emerging from behind a convenience store to deter badly behaved tourists, in the town of Fujikawaguchiko, Yamanashi prefecture on May 21, 2024. (Photo by Kazuhiro NOGI / AFP)
Workers install a barrier to block the sight of Japan's Mount Fuji emerging from behind a convenience store to deter badly behaved tourists, in the town of Fujikawaguchiko, Yamanashi prefecture on May 21, 2024. (Photo by Kazuhiro NOGI / AFP)

A Japanese town mounted a large mesh barrier at a popular viewing spot for Mount Fuji on Tuesday, to deter photo-taking by an ever-growing number of tourists, Agence France Presse reported.

Japan's most famous sight can be seen for miles around, but Fujikawaguchiko locals are fed up with streams of mostly foreign visitors littering, trespassing and breaking traffic rules in their hunt for a photo to share on social media.

Parking illegally and ignoring a smoking ban, they would cram a pavement to shoot the snow-capped mountain, which soars photogenically into the sky from behind a convenience store, residents said.

Workers began putting the black netting measuring 2.5 by 20 meters in place on Tuesday, and by late morning they were already done, an AFP reporter at the scene said.

"I hope that the net will prevent dangerous activities," resident Michie Motomochi, 41, who runs a traditional Japanese sweet shop, told AFP.

"I think it's disappointing that they are putting it up. It's obviously an iconic shot," said Christina Roys, 36, a tourist from New Zealand.

"But it's completely understandable. We were here last night, managing to get the last shot before they were putting up the wall, and there were so many people," she said.

"It's quite dangerous because of the traffic coming through. There are other spots where you can get the shot of the mountain."

- Online bookings -

Record numbers of overseas tourists are coming to Japan, where monthly visitors exceeded three million for the first time in March and then again in April.

But as in other tourist hotspots, such as Venice -- which recently launched a trial of entry fees for day visitors -- the influx has not been universally welcomed.

In Japan's ancient capital of Kyoto, locals have complained of tourists harassing the city's famed geisha.

And hikers using the most popular route to climb Mount Fuji this summer will be charged 2,000 yen ($13) each, with entries capped at 4,000 to ease congestion.

A new online booking system for the mountain's Yoshida trail opened on Monday to guarantee hikers entry through a new gate, although 1,000 places a day will be kept for day-of entries.

Mount Fuji is covered in snow most of the year, but during the July-September hiking season, more than 220,000 visitors trudge up its steep, rocky slopes.

Many climb through the night to see the sunrise, and some attempt to reach the 3,776-meter (12,388-foot) summit without breaks, becoming sick or injured as a result.

Regional officials have raised safety and environmental concerns linked to overcrowding on the active volcano, a symbol of Japan and a once-peaceful pilgrimage site.

Residents near other popular photo spots in the region, including the so-called Fuji Dream Bridge, have also reportedly complained about overtourism in recent weeks.

One tour operator that offers day trips from Tokyo to the Mount Fuji area told AFP they are taking visitors to another Lawson store nearby where a similar view can be seen, but there are fewer nearby residents.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”